Lilly expands radiopharmaceutical portfolio with $1.4B Point Biopharma deal

The transaction has been approved by the board of directors at both companies and Lilly said it expects the deal to close near the end of the year.

Related Keywords

Eli Lilly ,Jacob Van Naarden ,Drug Administration ,Point Biopharma ,Sigilon Therapeutics ,Bay Area Based ,Dice Therapeutics ,